NO20016046L - Administrering av ikke-orale androgene steroider til kvinner - Google Patents

Administrering av ikke-orale androgene steroider til kvinner

Info

Publication number
NO20016046L
NO20016046L NO20016046A NO20016046A NO20016046L NO 20016046 L NO20016046 L NO 20016046L NO 20016046 A NO20016046 A NO 20016046A NO 20016046 A NO20016046 A NO 20016046A NO 20016046 L NO20016046 L NO 20016046L
Authority
NO
Norway
Prior art keywords
women
administration
androgenic steroids
oral androgenic
oral
Prior art date
Application number
NO20016046A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016046D0 (no
Inventor
Theresa Rosario-Jansen
Norman A Mazer
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of NO20016046D0 publication Critical patent/NO20016046D0/no
Publication of NO20016046L publication Critical patent/NO20016046L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20016046A 1999-06-11 2001-12-11 Administrering av ikke-orale androgene steroider til kvinner NO20016046L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13885199P 1999-06-11 1999-06-11
US13932399P 1999-06-11 1999-06-11
US13885499P 1999-06-11 1999-06-11
PCT/US2000/015834 WO2000076522A1 (fr) 1999-06-11 2000-06-09 Administration de steroides androgenes non oraux aux femmes

Publications (2)

Publication Number Publication Date
NO20016046D0 NO20016046D0 (no) 2001-12-11
NO20016046L true NO20016046L (no) 2002-02-06

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016046A NO20016046L (no) 1999-06-11 2001-12-11 Administrering av ikke-orale androgene steroider til kvinner

Country Status (25)

Country Link
US (3) US6583129B1 (fr)
EP (1) EP1189619A4 (fr)
JP (2) JP5184727B2 (fr)
KR (2) KR20020011437A (fr)
CN (1) CN1220491C (fr)
AR (1) AR024566A1 (fr)
AU (1) AU775145B2 (fr)
BR (1) BR0011740A (fr)
CA (1) CA2376797C (fr)
CO (1) CO5180583A1 (fr)
CZ (1) CZ299198B6 (fr)
HK (1) HK1048269B (fr)
HU (1) HUP0301813A2 (fr)
IL (1) IL147010A0 (fr)
MX (1) MXPA01012769A (fr)
MY (1) MY126960A (fr)
NO (1) NO20016046L (fr)
NZ (1) NZ516502A (fr)
PE (1) PE20010404A1 (fr)
PL (1) PL352250A1 (fr)
SA (1) SA00210404B1 (fr)
SK (1) SK18212001A3 (fr)
TR (1) TR200200406T2 (fr)
TW (1) TWI281398B (fr)
WO (1) WO2000076522A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (fr) * 1995-10-06 1997-04-10 Arch Development Corporation Procedes et compositions de stimulation virale d'elimination de cellules
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
MXPA01012769A (es) * 1999-06-11 2003-06-24 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales para mujeres.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
CA2453337C (fr) * 2001-07-09 2012-08-28 Zonagen, Inc. Methodes et materiaux destines au traitement de la deficience en testosterone chez l'homme
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
WO2003030894A1 (fr) * 2001-10-11 2003-04-17 Alcon, Inc. Methodes de traitement des yeux secs
EP1441707A1 (fr) * 2001-11-09 2004-08-04 Pharmacia AB Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
CA2481310A1 (fr) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Therapie oestrogenique a diminution graduelle
EP1350541A1 (fr) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Emploi de déhydro-épiandrosterone et d'un dérivé d'estradiol pour préparer un médicament pour le traitement des troubles climactériques de la postménopause
US20030236284A1 (en) * 2002-06-14 2003-12-25 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
EP2305308A1 (fr) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remèdes à des affections, à usage ophtalmique
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
EP1776098A1 (fr) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphène pour le traitement de l'hypertrophie benigne de la prostate, du cancer de la prostate, de l'hypogonadisme,des taux eleves de triglycéride et de cholestérol
MX2007004830A (es) * 2004-10-20 2007-10-04 Endorech Inc Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de resequedad vaginal y disfuncion sexu
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
CN101115477A (zh) * 2005-02-04 2008-01-30 雷普罗斯治疗公司 用反式氯米芬治疗男性不育症的方法和物质
CN101252936A (zh) * 2005-03-02 2008-08-27 奈森特医药公司 眼用组合物的药学可接受的载体
RU2413508C2 (ru) * 2005-03-22 2011-03-10 Репрос Терапьютикс Инк. Режимы дозирования транс-кломифена
WO2007012815A1 (fr) * 2005-07-27 2007-02-01 Ingenia Technology Limited Verification d'authenticite
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
AU2007304471B2 (en) 2006-10-04 2012-09-06 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
ME00996B (fr) 2007-10-16 2012-10-20 Repros Therapeutics Inc Traitement d'un syndrome métabolique par trans-clomiphène
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
WO2009142699A1 (fr) * 2008-05-19 2009-11-26 The Procter & Gamble Company Traitement de l’insuffisance cardiaque chez les femmes
US9572817B2 (en) * 2008-07-04 2017-02-21 The Heart Research Institute Ltd. Use of androgens for vascular regeneration and endothelial repair
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2013012430A1 (fr) * 2011-07-19 2013-01-24 Riepl Michael S Gel à libération contrôlée bioadhésif de dhea
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン
CA2893761C (fr) 2012-12-05 2021-03-02 Ge Nutrients, Inc. Utilisation d'extrait de fenugrec pour augmenter la libido chez la femme
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2014149998A1 (fr) * 2013-03-15 2014-09-25 Lin, Qing Administration systémique d'androgène dans le traitement du syndrome de l'oeil sec
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (fr) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
EP3737374B1 (fr) 2018-01-10 2024-04-03 Celista Pharmaceuticals Llc Pulvérisation transdermique de testostérone avec film
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US4210664A (en) * 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
EP0462189B1 (fr) 1989-03-10 1995-09-27 Endorecherche Inc. Therapie combinee pour le traitement de maladies sensibles a l'oestrogene
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
WO1999063973A2 (fr) 1998-06-11 1999-12-16 Endorecherche, Inc. COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS POUR L'ANDROST-5-ENE-3β,17β-DIOL
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
MXPA01012769A (es) * 1999-06-11 2003-06-24 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales para mujeres.

Also Published As

Publication number Publication date
IL147010A0 (en) 2002-08-14
WO2000076522A1 (fr) 2000-12-21
CN1220491C (zh) 2005-09-28
CA2376797A1 (fr) 2000-12-21
MY126960A (en) 2006-11-30
NO20016046D0 (no) 2001-12-11
AU775145B2 (en) 2004-07-22
CZ299198B6 (cs) 2008-05-14
US20030153540A1 (en) 2003-08-14
SA00210404B1 (ar) 2006-08-21
US8551516B2 (en) 2013-10-08
JP2003505345A (ja) 2003-02-12
KR20070063609A (ko) 2007-06-19
EP1189619A1 (fr) 2002-03-27
CO5180583A1 (es) 2002-07-30
CA2376797C (fr) 2011-03-22
SK18212001A3 (sk) 2002-04-04
TR200200406T2 (tr) 2002-06-21
HUP0301813A2 (hu) 2003-09-29
AU5475800A (en) 2001-01-02
HK1048269B (zh) 2006-01-13
MXPA01012769A (es) 2003-06-24
JP2013049682A (ja) 2013-03-14
HK1048269A1 (en) 2003-03-28
EP1189619A4 (fr) 2004-06-09
CN1367698A (zh) 2002-09-04
JP5184727B2 (ja) 2013-04-17
PL352250A1 (en) 2003-08-11
AR024566A1 (es) 2002-10-16
PE20010404A1 (es) 2001-04-09
US7186706B2 (en) 2007-03-06
TWI281398B (en) 2007-05-21
CZ20014499A3 (cs) 2002-05-15
NZ516502A (en) 2004-03-26
BR0011740A (pt) 2002-05-14
US20070190120A1 (en) 2007-08-16
US6583129B1 (en) 2003-06-24
KR20020011437A (ko) 2002-02-08

Similar Documents

Publication Publication Date Title
NO20016046L (no) Administrering av ikke-orale androgene steroider til kvinner
NO20022681D0 (no) Kontinuerlig fremstilling av silicabaserte mikrogeler
HUP0100121A3 (en) Pharmaceutical compositions for the treatment of conditions responsive to testosterone elevation
NO20002635L (no) Fremstilling av sterol- og stanolestrer
PL351261A1 (en) Derivatives of indigoid bisindoles
TW450031U (en) Trousers of convenience
NO20020365D0 (no) Oligonukleotider for inhibering av ekspresjonen av humant EG5
HUP0201872A2 (en) Steroid compounds and pharmaceutical compositions of the same
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
NO20015505D0 (no) Fremstilling av komplekse karbohydrater
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20013857L (no) Krystallinsk form av Eplerenon
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
ZA200110181B (en) Administration of non-oral androgenic steroids to women.
NO20014383L (no) Fremgangsmåte for fremstilling av syklo-(Asp-DPhe-NMeVal-Arg- Gly)
AU3650900A (en) Preparation of saturated phytosterols
TW390163U (en) Improved structure of closet panel with front-and-reverse placement variations
TW433693U (en) Combined structure of refined parts
TW386360U (en) Improvement of underwear
TW389290U (en) Improved structure of plumbing union
TW430159U (en) Structure of universal synchronous bus
TW445775U (en) Improved structure of bra
TW494728U (en) Improved structure of bra
TW418623U (en) Structure of aglet
CA96058S (en) Set of bathtub supports

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application